Aaron Gal
Stock Analyst at Bernstein
(2.15)
# 2,708
Out of 4,711 analysts
22
Total ratings
53.85%
Success rate
5.15%
Average return
Main Sectors:
Stocks Rated by Aaron Gal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences | Initiates: Outperform | $105 | $92.57 | +13.43% | 6 | Oct 17, 2024 | |
| ABBV AbbVie | Initiates: Market Perform | $203 | $175.58 | +15.62% | 2 | Oct 17, 2024 | |
| AMGN Amgen | Initiates: Outperform | $380 | $263.38 | +44.28% | 3 | Oct 17, 2024 | |
| REGN Regeneron Pharmaceuticals | Initiates: Outperform | $1,125 | $701.85 | +60.29% | 3 | Mar 11, 2024 | |
| BIIB Biogen | Upgrades: Outperform | $500 | $146.47 | +241.37% | 6 | Jun 11, 2021 | |
| VTRS Viatris | Initiates: Market Perform | $21 | $12.52 | +67.73% | 1 | Dec 14, 2020 | |
| TEVA Teva Pharmaceutical | Downgrades: Market Perform | n/a | $22.09 | - | 1 | Aug 4, 2017 |
Gilead Sciences
Oct 17, 2024
Initiates: Outperform
Price Target: $105
Current: $92.57
Upside: +13.43%
AbbVie
Oct 17, 2024
Initiates: Market Perform
Price Target: $203
Current: $175.58
Upside: +15.62%
Amgen
Oct 17, 2024
Initiates: Outperform
Price Target: $380
Current: $263.38
Upside: +44.28%
Regeneron Pharmaceuticals
Mar 11, 2024
Initiates: Outperform
Price Target: $1,125
Current: $701.85
Upside: +60.29%
Biogen
Jun 11, 2021
Upgrades: Outperform
Price Target: $500
Current: $146.47
Upside: +241.37%
Viatris
Dec 14, 2020
Initiates: Market Perform
Price Target: $21
Current: $12.52
Upside: +67.73%
Teva Pharmaceutical
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $22.09
Upside: -